iVIEW Therapeutics
iVIEW Therapeutics Inc. is a clinical-stage ophthalmology-focused therapeutics company based in Cranbury, New Jersey. The company is committed to the treatment of ocular diseases with high unmet medical needs through innovative small molecule drugs and gene therapy approaches. Their focus on novel mechanisms of action and proprietary drug delivery technology platforms allows them to develop highly differentiated assets with potentially superior target product profiles. Their portfolio includes products for Acute Infectious Conjunctivitis, Dry Eye Disease, Myopia, and Glaucoma.
Industries
Nr. of Employees
small (1-50)
Patents
Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
US-12029743-B2
View DetailsPharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
US-11986491-B2
View DetailsDi-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort
US-11684628-B2
View DetailsIn situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
US-11547659-B2
View DetailsRapid-deposition thin-film forming compositions as effective wound care treatment
US-11471481-B2
View Details
Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
US-12029743-B2
View DetailsPharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
US-11986491-B2
View DetailsDi-isopropyl-phosphinoyl-alkanes (DAPA) compounds as topical agents for the treatment of sensory discomfort
US-11684628-B2
View DetailsIn situ gel-forming pharmaceutical compositions and uses thereof for sinus diseases
US-11547659-B2
View DetailsRapid-deposition thin-film forming compositions as effective wound care treatment
US-11471481-B2
View DetailsProducts
Ophthalmic eyelid wipe for dry eye (IND-cleared)
Topical eyelid-wipe formulation developed to treat signs and symptoms of dry eye disease; cleared for clinical investigation via IND by FDA.
Therapeutic candidate for fungal keratitis (FDA orphan designation)
Ophthalmic therapeutic candidate addressing fungal keratitis that has received orphan drug designation from the U.S. FDA.
Pipeline candidates for acute infectious conjunctivitis, dry eye, myopia and glaucoma
Portfolio of development-stage ophthalmic candidates addressing multiple indications including acute infectious conjunctivitis, dry eye disease, myopia and glaucoma.
IVW-1001
IVW-1001 is a selective TRPM8 agonist from the cryosims series that produces cooling sensations and has shown improvement in dry eye disease signs and symptoms in clinical trials. It increases tear production within 5-20 minutes and has longer lasting effects after 2 weeks without adverse events.
IVW-1201
A novel sustained release povidone iodine gel forming solution for the treatment of adenoviral conjunctivitis, in Phase II clinical trials.
IVW-1802
An ophthalmic solution developed with proprietary drug delivery technology targeting myopia with higher M1/4 receptor affinity and reduced side effects compared to atropine.
Ophthalmic eyelid wipe for dry eye (IND-cleared)
Topical eyelid-wipe formulation developed to treat signs and symptoms of dry eye disease; cleared for clinical investigation via IND by FDA.
Therapeutic candidate for fungal keratitis (FDA orphan designation)
Ophthalmic therapeutic candidate addressing fungal keratitis that has received orphan drug designation from the U.S. FDA.
Pipeline candidates for acute infectious conjunctivitis, dry eye, myopia and glaucoma
Portfolio of development-stage ophthalmic candidates addressing multiple indications including acute infectious conjunctivitis, dry eye disease, myopia and glaucoma.
IVW-1001
IVW-1001 is a selective TRPM8 agonist from the cryosims series that produces cooling sensations and has shown improvement in dry eye disease signs and symptoms in clinical trials. It increases tear production within 5-20 minutes and has longer lasting effects after 2 weeks without adverse events.
IVW-1201
A novel sustained release povidone iodine gel forming solution for the treatment of adenoviral conjunctivitis, in Phase II clinical trials.
IVW-1802
An ophthalmic solution developed with proprietary drug delivery technology targeting myopia with higher M1/4 receptor affinity and reduced side effects compared to atropine.
Services
Presenting ophthalmic research at scientific meetings and participating in industry roundtables and forums to disseminate data and engage collaborators.
Engagement in external collaborations for preclinical and clinical development of ophthalmic therapeutics and delivery platforms.
Presenting ophthalmic research at scientific meetings and participating in industry roundtables and forums to disseminate data and engage collaborators.
Engagement in external collaborations for preclinical and clinical development of ophthalmic therapeutics and delivery platforms.
Expertise Areas
- Clinical trial management for ophthalmology
- Regulatory strategy and FDA interactions (IND, orphan designation)
- Ocular gene therapy development
- Small-molecule discovery for eye diseases
Key Technologies
- Ocular gene therapy
- TRPM8 ion-channel modulation
- Target-based small-molecule discovery
- In-situ gelling ophthalmic formulations